Depressive Symptoms and the Effectiveness of a Urate-Lowering Therapy in a Clinical Trial. [PDF]
ACR Open Rheumatol, 2020 ObjectiveThis ancillary study examined the impact of depressive symptoms on the effectiveness of a urate‐lowering therapy in the context of a clinical trial.MethodsParticipants included 67 adults (ages 18–40) with elevated blood pressure who were enrolled in a double‐blind, randomized, crossover clinical trial evaluating the effectiveness of ...
Mrug S +6 more
europepmc +5 more sources
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study [PDF]
BMC NephrologyBackground Uncontrolled gout can cause articular impairment but is also associated with a global and cardiovascular excess mortality, especially in dialysis population.
Alexia Steelandt +7 more
doaj +2 more sources
Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future [PDF]
Научно-практическая ревматология, 2022 The article provides an overview of new and promising drugs aimed at anti-inflammatory and urate-lowering therapy of gout, both already registered and used in clinical practice, and at the stages of implementation or clinical research and demonstrating ...
A. A. Garanin +2 more
doaj +2 more sources
Frontiers in Pharmacology, 2022 Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda +15 more
doaj +1 more source
The impact of urate-lowering therapy on kidney function (IMPULsKF)
Počki, 2017 The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (CKD) progression measured by estimated glomerular filtration rate and albuminuria in 180 patients ...
D.D. Ivanov
openaire +3 more sources
Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. [PDF]
Arthritis Care Res (Hoboken)BACKGROUND/AIMS: Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate ...
Dalbeth N +19 more
europepmc +2 more sources
The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study. [PDF]
J Inflamm Res, 2023 Lei Pang,1– 4,* Xiaomei Xue,1– 4,* Yuwei He,1– 4 Can Wang,1– 4 Lin Han,1– 4 Maichao Li,1– 4 Han Qi,1– 4 Changgui Li,1– 4 Jie Lu1– 4 1Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao ...
Pang L +8 more
europepmc +2 more sources
The many faces of gout: modern treatment concepts
Клинический разбор в общей медицине, 2021 Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation.
Irina N. Bobkova, Elena S. Kamyshova
doaj +1 more source
Adherence with urate-lowering therapies for the treatment of gout [PDF]
Arthritis Research & Therapy, 2009 Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Harrold, Leslie R +6 more
openaire +3 more sources
Rational use of recommendations for urate-lowering therapy: clinical examples [PDF]
, 2022 The results of gout therapy in many patients remain unsatisfactory, despite the availability of drugs and recommendations for its treatment. In addition to poor adherence to treatment by patients, medical errors and other reasons influence this situation.
O. V. Zhelyabina, M. S. Eliseev
core +1 more source